Jenscare Scientific Co., Ltd. announced that recently, the first clinical implantation of LuX-Valve Plus, proprietary transjugular tricuspid valve replacement product, has been successfully completed at Rede D' OR Hospital in Brazil. The clinical interventional procedure was smooth. Immediately after the operation, it was shown that the implanted valve in the patient was stable, without regurgitation or paravalvular leakage, and additionally the mitral valve regurgitation had also been alleviated.

The patient's clinical performance, cardiac function and quality of life improved significantly after the operation. Professor Vincius Esteves, the cardiologist from Rede D' OR Hospital, highly recognizes LuX-Valve Plus and its clinical interventional procedure process, commenting that this is the first application of transcatheter tricuspid valve intervention replacement in Latin America, and the successful application of LuX-Valve Plus would bring possibility of treatment of tricuspid valve regurgitation patients in Latin America. The success of the implantation demonstrates the wide applicability, high reliability, and simple operation process of LuX-Valve Plus.

The Company is in the process of facilitating its Lux-Valve product series to be approved by the National Medical Products Administration in China for commercialization, its clinical trials for European CE marking and U.S. Food and Drug Administration registration. Meanwhile, the Company also continues to promote the global commercialization of this product and the realization of the Company's internationalization strategy.